Bristol Myers Squibb, Bayer Stocks Hit The Deck On Blood Thinner FlopsInvestors Business Daily • 08/29/22
Late-Breaking Results From Phase 2 AXIOMATIC-SSP Study of Milvexian, an Investigational Oral Factor XIa Inhibitor, Show Favorable Antithrombotic Profile in Combination With Dual Antiplatelet TherapyBusiness Wire • 08/28/22
PathAI Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers SquibbBusiness Wire • 08/25/22
Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology PortfolioBusiness Wire • 08/17/22
Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point TherapeuticsBusiness Wire • 08/16/22
10 defensive stocks that can also provide you with growth and dividends over the long termMarket Watch • 08/10/22
Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple MyelomaBusiness Wire • 08/10/22
Bristol Myers Squibb to Host Virtual Investor Event to Discuss ESC 2022 HighlightsBusiness Wire • 08/03/22
Famed "Big Short" Investor Loves This Multibillion-Dollar Company -- Should You?The Motley Fool • 08/03/22
These eight health-care stocks can keep you invested in the market with less worryMarket Watch • 08/02/22